CN104257762A - Drug combination and purpose for preventing and curing osteoporosis - Google Patents
Drug combination and purpose for preventing and curing osteoporosis Download PDFInfo
- Publication number
- CN104257762A CN104257762A CN201410551423.2A CN201410551423A CN104257762A CN 104257762 A CN104257762 A CN 104257762A CN 201410551423 A CN201410551423 A CN 201410551423A CN 104257762 A CN104257762 A CN 104257762A
- Authority
- CN
- China
- Prior art keywords
- cervi
- lupuli
- flos
- glycopeptide
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000001132 Osteoporosis Diseases 0.000 title abstract description 23
- 239000000890 drug combination Substances 0.000 title abstract description 4
- 102000002068 Glycopeptides Human genes 0.000 claims abstract description 34
- 108010015899 Glycopeptides Proteins 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 24
- 229930003944 flavone Natural products 0.000 claims abstract description 20
- 235000011949 flavones Nutrition 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims abstract 2
- 239000007902 hard capsule Substances 0.000 claims abstract 2
- 239000006187 pill Substances 0.000 claims abstract 2
- 239000007901 soft capsule Substances 0.000 claims abstract 2
- 239000003826 tablet Substances 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 241000628997 Flos Species 0.000 claims description 40
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000000284 extract Substances 0.000 claims description 27
- 150000001669 calcium Chemical class 0.000 claims description 20
- 150000002213 flavones Chemical class 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 10
- 230000001009 osteoporotic effect Effects 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 7
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- -1 let cool Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000003643 water by type Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000011575 calcium Substances 0.000 abstract description 25
- 229910052791 calcium Inorganic materials 0.000 abstract description 25
- 210000000988 bone and bone Anatomy 0.000 abstract description 24
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 12
- 210000003734 kidney Anatomy 0.000 abstract description 12
- 229930003316 Vitamin D Natural products 0.000 abstract description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract description 8
- 235000019166 vitamin D Nutrition 0.000 abstract description 8
- 239000011710 vitamin D Substances 0.000 abstract description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract description 8
- 229940046008 vitamin d Drugs 0.000 abstract description 8
- 210000004185 liver Anatomy 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 4
- 210000003205 muscle Anatomy 0.000 abstract description 3
- 102000008186 Collagen Human genes 0.000 abstract description 2
- 108010035532 Collagen Proteins 0.000 abstract description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 2
- 230000009471 action Effects 0.000 abstract description 2
- 229920001436 collagen Polymers 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 150000002212 flavone derivatives Chemical class 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 2
- 230000009469 supplementation Effects 0.000 abstract 3
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 241001122767 Theaceae Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 239000000745 gonadal hormone Substances 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000000689 upper leg Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 238000009835 boiling Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000037182 bone density Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 208000006386 Bone Resorption Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000024279 bone resorption Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- LWFUFLREGJMOIZ-UHFFFAOYSA-N 3,5-dinitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O LWFUFLREGJMOIZ-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000282985 Cervus Species 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 3
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 3
- 241000282994 Cervidae Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- FUSADYLVRMROPL-UHFFFAOYSA-N demethylxanthohumol Natural products CC(C)=CCC1=C(O)C=C(O)C(C(=O)C=CC=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UHFFFAOYSA-N 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229930008679 prenylflavonoid Natural products 0.000 description 3
- 150000007951 prenylflavonoids Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 241000283026 Cervus elaphus Species 0.000 description 2
- 241000283007 Cervus nippon Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010039984 Senile osteoporosis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 238000004380 ashing Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- UVBDKJHYMQEAQV-UHFFFAOYSA-N xanthohumol Natural products OC1=C(CC=C(C)C)C(OC)=CC(OC)=C1C(=O)C=CC1=CC=C(O)C=C1 UVBDKJHYMQEAQV-UHFFFAOYSA-N 0.000 description 2
- 235000008209 xanthohumol Nutrition 0.000 description 2
- ORXQGKIUCDPEAJ-YRNVUSSQSA-N xanthohumol Chemical compound COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 ORXQGKIUCDPEAJ-YRNVUSSQSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000735234 Ligustrum Species 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002968 anti-fracture Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001203 anti-plasmodial effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004221 bone function Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 230000007691 collagen metabolic process Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- JFCCOFVNZMTDAN-UHFFFAOYSA-N dehydrocycloxanthohumol hydrate Natural products COC1=CC2OC(C)(C)C(O)CC2C(=C1C(=O)C=Cc3ccc(O)cc3)O JFCCOFVNZMTDAN-UHFFFAOYSA-N 0.000 description 1
- FUSADYLVRMROPL-UXBLZVDNSA-N desmethylxanthohumol Chemical compound CC(C)=CCC1=C(O)C=C(O)C(C(=O)\C=C\C=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UXBLZVDNSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- YKGCBLWILMDSAV-SFHVURJKSA-N isoxanthohumol Chemical compound C1([C@H]2OC=3C(CC=C(C)C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1 YKGCBLWILMDSAV-SFHVURJKSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 229940074446 sodium potassium tartrate tetrahydrate Drugs 0.000 description 1
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- GUQGMEWOCKDLDE-RMKNXTFCSA-N xanthohumol B Chemical compound COC1=CC=2OC(C)(C)C(O)CC=2C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 GUQGMEWOCKDLDE-RMKNXTFCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a natural drug combination for assisting in preventing and curing osteoporosis. The drug combination is characterized by comprising hop general flavone, ox bone glycopeptides, ox bone active calcium and glossy privet fruit extractive. The combination takes kidney tonifying, muscle and bone strengthening, qi replenishing to invigorate the spleen and blood activating and liver coordinating in Chinese medicine as a base point, combines different action mechanisms, such as supplementing calcium supplementation, supplementation of vitamin D and activated products thereof, supplementation of collagen and gonadal hormone concentration adjustment, utilizes the synergistic effect of all the constituents, achieves the effect of preventing and curing osteoporosis, can be prepared into oral preparation, such as hard capsules, soft capsules, tablets, granules, powders, pills, tea bags and medicinal liquor, and can be applied to Chinese patent medicine or health food.
Description
Technical field
The invention relates to one to have and contribute to the osteoporotic natural drug composition of prevention and therapy, belong to medicine and field of food.
Background technology
Osteoporosis (osteoporosis, OP) be a kind of with Low BMD and osseous tissue Microstructure Fracture for feature, cause sclerotin fragility to increase and be easy to the general bone metabolic disease of fracturing.Primary disease is common in old people, but each period at age all can fall ill.Osteoporosis can be divided into constitutional and Secondary cases two class.Primary osteoporosis means other illness not causing primary disease; Secondary osteoporosis is then that the osseous tissue amount caused due to various general or endocrine metabolism disease reduces.Along with social population's aging day by day, the sickness rate of osteoporosis increases day by day, huge misery is brought to patient, white elephant be also result in family and society, that protect against osteoporosis is pre-, the anti-fracture of medical circle is prevented myocardial infarction with treatment hyperlipidemia, is treated hypertension prevention apoplexy and put in status of equal importance, and the preventing and controlling of osteoporosis have become one of the important public hygiene problem of social concerns and the most popular research field of medical circle.Osteoporotic factor is caused mainly to comprise
:inherited genetic factors; The shortage of calcium and vitamin D; Oestrogen deficiencies; Hypoandrogenism and senescent deterioration.The 3 large classes such as calcium preparation, vitamin D and bone resorption depressant are mainly contained at present, by whole world extensive use after FDA approval for the osteoporotic medicine of prevention and therapy.For more serious case, adopt this 3 kinds of medicine use in conjunction, calcium preparation provides osteoplastic raw material, vitamin D promotes the absorption of intestinal calcium and suppresses the loss of bone calcium, bone resorption depressant can suppress the too fast bone resorption speed of post menopausal and senile osteoporosis, triple combination applies, and has the effect mutually coordinated.
Flos lupuli (Flos Humuli Lupuli) total flavones is from moraceae plants Flos lupuli (Flos Humuli Lupuli)
h. lupuluslinn. through ethanol extraction in, the flavones ingredient that purification by macroporous resin obtains.Chalcone, flavonoid and flavanoid is mainly containing flavones ingredient, comprise xanthohumol, isoxanthohumol, demethyl xanthohumol, Dehydrocycloxanthohumol hydrate, D, G, H, be the exclusive source of the natural prenylflavonoids found at present, become the main source of xanthohumol and other prenylflavonoids.Wherein prenylflavonoids is current the most effective phytoestrogen (Zhou Tian, brewing science and technology, the 8th phase in 2006); From at present research, Flos lupuli (Flos Humuli Lupuli) flavone has antiviral and antiplasmodial activities, antifungal, anticancer, estrogen-like effects, diglyceride Acetylase inhibitory action, antioxidation and bone resorption inhibitory action (Li Juan, Chinese herbal medicine, the 7th phase in 2008).
Os Cervi glycopeptide is animal in deer family Cervus nippon Temminck
cervus nippontemminck or Cervus elaphus linnaeus
cervus elaphusthe skeleton water high pressure extract of Linnaeus, after oils and fats, precipitate with ethanol, the glycopeptide compound obtained.Os Cervi is a kind of Chinese medicine, has effect of tonify deficiency, strong muscle, bone strengthening, is applicable to the diseases such as eipathia asthenia, marrow deficiency, anemia, rheumatism, extremity pain.Os Cervi glycopeptide has protection gastric mucosa, antiulcer, blood pressure lowering, prevention of osteoporosis disease, promotes skin collagen metabolism, antioxidation, health care wait for a long time physiological function.
Os Cervi activated calcium is animal in deer family Cervus nippon Temminck
cervus nippontemminck or Cervus elaphus linnaeus
cervus elaphusthe skeleton of Linnaeus adopts homogenization process to smash after extracting Os Cervi glycopeptide, drying forms.
Fructus Ligustri Lucidi extract be Oleaceae plants Fructus Ligustri Lucidi (
ligustrum lucidumait) dry mature fruit utilizes ethanol extraction to obtain.Its nature and flavor sweetness and bitterness, cool, enter liver, kidney channel, there is effect of nourishing the liver and kidney, improving eyesight black hair, be used for the treatment of the diseases such as vertigo and tinnitus, soreness of the waist and knees, early whitening of beard and hair, poor vision.Fructus Ligustri Lucidi is mainly containing triterpenes fat-soluble active ingredients such as oleanolic acid, water-soluble chemical component (the Wu Lijun such as secoiridoid glycoside and salidroside class, Botany Gazette, 1998,1st phase), vitamin D sample active substance and estrogen-like product, also containing a small amount of polysaccharide, phospholipid and inorganic elements.Modern pharmacological research shows, Fructus Ligustri Lucidi has nourishing the liver and kidney, antiinflammatory, raising immunity of organism, blood fat reducing and anti-aging effects (Jin Xiaoming, Chinese medicine information, the 2008,1st phase).
The present invention is made up of Flos lupuli (Flos Humuli Lupuli) total flavones, Os Cervi glycopeptide, Os Cervi activated calcium and Fructus Ligustri Lucidi extract.Belong to osteoporosis and suffering from a deficiency of the kidney, when being that the rule for the treatment of makes basic point with the kidney invigorating, in conjunction with the Couple herbs of modern age to osteoporosis, through the side's of tearing open experiment, several times screening adjustment and forming.Before the present patent application, do not find by Flos lupuli (Flos Humuli Lupuli) total flavones, Os Cervi glycopeptide, Os Cervi activated calcium, the compositions of Fructus Ligustri Lucidi extract composition has the report of protect against osteoporosis.
Summary of the invention
Compositions of the present invention is formed by Flos lupuli (Flos Humuli Lupuli) total flavones, Os Cervi glycopeptide, Os Cervi activated calcium and Fructus Ligustri Lucidi extract prescription, with traditional Chinese medical science the kidney invigorating, bone and muscle strengthening, replenishing QI to invigorate the spleen, tune liver of invigorating blood circulation are basic point, set out in conjunction with the different mechanism of action such as supplement calcium, vitamin D and activated product thereof, replenishing collagen, sex hormone level regulation, comprehensive function, in body, embodies the advantage of drug combination, reaches the effect of good prevention and therapy osteoporosis.
In the present composition, Flos lupuli (Flos Humuli Lupuli) total flavones has sex hormone level adjustment, corrects bone metabolism disturbance and suppresses bone resorption, promoting calcareous utilization; Os Cervi glycopeptide nourishing YIN and benefiting blood, logical conception vessel and nourishing YIN for suppressing the hyperactive YANG, kidney tonifying promotes the production of body fluid, and provides a large amount of osseins, promotes the absorption of calcium; Os Cervi activated calcium provides calcium former, nourishing YIN for suppressing the hyperactive YANG same with Os Cervi glycopeptide, kidney tonifying bone strengthening; Fructus Ligustri Lucidi extract nourishing the liver and kidney, provides vitamin D sample active substance and estrogen-like product to promote the absorption of calcium simultaneously.Four kinds of different extract mechanisms of action are different, and mutually work in coordination with again, enhance curative effect, have obvious novelty and technological progress.An important feature of medicine of the present invention is containing abundant nutrition ionized calcium, animal glycopeptide and total flavones, triterpene acids, vitamin D sample active substance, estrogen, various trace elements etc. in medicament.Whole drug component negative and positive are trained mutually, and cold not dry, application crowd is extensive, are rather in step with for all diseases caused by deficiency of kidney-essence.We's four kinds of extract couplings can regulate Ca,P metabolism in human body, and especially along with the age increases, hormone in vivo level declines and causes the loss of body calcium, and energy the kidney invigorating, reuniting the fractured tendons and bones, blood circulation regulating, improve the symptom of aching pain in waist and back, the foot and knee being feeble.The special senile osteoporosis that can make fundamentally obtains the effective treatment.The invention has the beneficial effects as follows: to improving middle-aged and elderly people, particularly in women's post menopausal body, calcium, phosphorus balance have facilitation, and energy the kidney invigorating, reuniting the fractured tendons and bones, blood circulation regulating, can improve the symptom of aching pain in waist and back, the foot and knee being feeble.Can bone density be significantly improved, bone mineral content, there is the osteoporotic curative effect of significant treatment.The present invention has evident in efficacy, and cost is low, formula is clearly simple, and one-tenth is distinguished one from the other, system easy to control the quality, little to other organ-tissue toxic and side effects, can long-term taking, have keep fit, strong bone function, all have significant curative effect to the disease such as osteoporosis, fracture.
Innovative point of the present invention is: the present invention utilizes edible Flos lupuli (Flos Humuli Lupuli) for primary raw material first, be equipped with again can be used for health food Os Cervi glycopeptide, Os Cervi activated calcium, Fructus Ligustri Lucidi extract composition compositions for prevention and therapy osteoporosis, there is obvious novelty.Take full advantage of Os Cervi resource simultaneously, make outstanding contributions for deer industry further develops.
Another innovative point of the present invention is: Os Cervi passes through and extracts, except oils and fats by the present invention first, obtain respectively providing human body easily to absorb Os Cervi glycopeptide and free Os Cervi activated calcium, this Os Cervi glycopeptide prepared through high pressure extract and more direct the pulverizing by Os Cervi of Os Cervi activated calcium take absorption of human body of being more convenient for.Meanwhile, Os Cervi is through high pressure extract, and concentrated, after drying, the pathogen in Os Cervi obtains removing, takes safety, and this is another beneficial effect of the present invention.The content of the middle polysaccharide of the Os Cervi glycopeptide extracted is 30-70%, and the content of protein is 35-75%.
The present invention relates to Os Cervi glycopeptide and Os Cervi activated calcium, be not limited in Os Cervi glycopeptide and Os Cervi activated calcium, when this prescription forms, Os Bovis seu Bubali and Os Caprae seu Ovis also have similar pharmacologically active.Os Cervi is replaced with Os Bovis seu Bubali and Os Caprae seu Ovis has the effect identical with the present invention.
Chinese medicine composition of the present invention is obviously better than positive control medicine LONGMU ZHUANGGU CHONGJI and fully stocked wood board Os Cervi calcium tablet to the prevention effect of osteoporosis, has obvious technological progress.
The present invention has pure natural relative to prior art, determined curative effect, has no side effect, the advantage such as taking convenience.
The invention also discloses one and have the osteoporotic natural drug composition of auxiliary prevention and therapy, it is characterized in that, it is made up of Flos lupuli (Flos Humuli Lupuli) total flavones 50-150 part, Os Cervi glycopeptide 25-100 part, Os Cervi activated calcium 150-400 part, Fructus Ligustri Lucidi extract 150-400 part, preferably beer flower total flavones 100 parts, Os Cervi glycopeptide 50 parts, Os Cervi activated calcium 200 parts, Fructus Ligustri Lucidi extract 200 parts.
The preparation method of natural drug composition of the present invention is as follows:
(1) Flos lupuli (Flos Humuli Lupuli) 30-95% alcohol reflux 2-3 time, each 2-3 hour, filter, filtrate recycling ethanol, the AB-8 macroporous resin column of concentrated solution by anticipating, first use deionized water eluting, use 60-90% ethanol elution again, collect ethanol elution, reclaim ethanol, drying, obtains Flos lupuli (Flos Humuli Lupuli) total flavones;
(2) Os Cervi clear water is cleaned, and is ground into coarse powder, in autoclave, carries out high pressure extract 3 hours with the deionized water of 5 times amount, filter, filtering residue add again 4 times amount deionized waters continue to be extracted into Os Cervi loosen frangible till, filter, merge twice filtrate, let cool, oil removing, concentrated, the concentrated solution alcohol settling of 5 times amount, filter, dry, obtain Os Cervi glycopeptide;
(3) the Os Cervi refiner after extraction glycopeptide is broken into homogenate, dry, pulverize, cross 200 mesh sieves, obtain Os Cervi activated calcium;
(4) Fructus Ligustri Lucidi 4-10 times of 40-90% alcohol reflux 2-3 time, each 1-3 hour, filters, filtrate recycling ethanol, concentrated, dry, obtains Fructus Ligustri Lucidi extract;
(5) by Flos lupuli (Flos Humuli Lupuli) total flavones, Os Cervi glycopeptide, Os Cervi activated calcium, Fructus Ligustri Lucidi extract proportionally mix homogeneously, add auxiliary materials and mixing, to obtain final product.
In order to realize above technical scheme, verified by once method:
Determination of polysaccharide in Os Cervi glycopeptide
The preparation of DNS reagent: get 3,5-dinitrosalicylic acid 6. 5g, be dissolved in a small amount of water, move in 1000mL volumetric flask, adds 2mol/ L NaOH solution 325m L, then adds people 45g glycerol, shake up, be settled to scale.
The extraction precision of Os Cervi glycopeptide total sugar takes Os Cervi glycopeptide 200mg and puts in 100mL test tube, adds 16mol/L HCl20mL, distilled water 30mL, boiling water boiling 60min, filters, adds 1 phenolphthalein reagent, be neutralized to blush with 10%NaOH solution, standardize solution is in 250ml volumetric flask, stand-by.
The preparation precision of reference substance takes dextrose standard sample in right amount, is dissolved in water, makes the reference substance solution of 0.5mg/m L.
Glucose control product 0,0.5,1.0,1.2,1.5,2.0mL are drawn in the preparation of standard curve respectively, put in 25mL volumetric flask, add water 2.0,1.5,1.0,0.8,0.5 respectively, 0 m L, respectively add 3 m L DNS reagent, shake up, in boiling water boiling 5m in, cooling, is settled to scale with distilled water.Measure at 503nm place, calculate regression equation.
Mensuration is got 1.0mL extracting solution and is put in 25ml volumetric flask from above-mentioned liquid to be measured, then adds 1.0mL water, and adds DNS 3mL, and after boiling water boiling 5min, flowing water cooling, adds water and be settled to 25mL, measure at 503nm place, calculates content.
Protein content determination in Os Cervi glycopeptide
The preparation of reagent: reagent first (A): 10g sodium carbonate, 2g sodium hydroxide and 0.25g sodium potassium tartrate tetrahydrate adding distil water are made into 500mL solution, reagent first (B): 0.5g copper sulphate dissolves is in 100mL distilled water, and 50 parts (A) and 1 part (B) are mixed into reagent first by each used time.Reagent second: 100g sodium tungstate, 25g sodium molybdate and 700mL distilled water, add 50mL85% phosphoric acid again, the dense HCl of 100mL fully mixes, and after 10 h that reflux, adds 150g lithium sulfate, 50 mL distilled water and number drop of liquid bromine, opening continues boiling 15min to drive away excessive bromine, is diluted to 1 L, filters after cooling, filtrate is preserved in brown bottle, is doubly reagent second with front dilution 1.
The preparation precision of reference substance solution takes 105 DEG C and is dried to constant weight bovine serum albumin reference substance, puts in measuring bottle, is dissolved in water and is diluted to scale, shaking up, and obtains (every 1 mL is containing bovine serum albumin 300 μ g).
The preparation of standard curve is got bovine serum albumin standard solution 0,0.4,0.8,1.6,2.0 mL and is added in 5 test tubes, standard solution moisturizing to 2 mL, add 5mL reagent first, shake up, static 10min, then 0.5mL reagent second is added, vibration immediately shakes up, after static 30 min, with standard solution the 1st pipe for contrast, according to spectrophotography (" Chinese Pharmacopoeia " 2010 editions annex VA), measure trap at 660 nm wavelength places, with the trap that bovine serum albumin μ g number is corresponding, calculate regression equation.
Assay method precision takes test sample, and to be configured to solution concentration be 600 μ g/mL, as need testing solution.The accurate need testing solution 1.0mL that draws adds water to 2mL, under sighting target directrix curve preparation from " adding 5 mL reagent first ", operates in accordance with the law, measures trap, by regression equation calculation protein content.
Composition of natural products of the present invention has prevents and treats osteoporosis function, is confirmed (testing Pharmaceutical composition used is the Pharmaceutical composition prepared in embodiment 1) by following pharmacodynamic experiment.
The test medicine present composition prepares according to example 1; Positive control drug LONGMU ZHUANGGU KELI is Wuhan JianMin Pharmaceutical Group Co., Ltd's product, lot number 1311001.Large dark woods board Os Cervi calcium tablet is Daqing Huake Company Limited. Pharmacy filiale's product, lot number: 130201.
Animal SD rat, female, three monthly ages, body weight 213 ± 21g, purchased from Jilin University's Experimental Animal Center, the quality certification numbers 13008.The quality certification number deletes also
Therapeutical effect on castrated rats osteoporosis disease: the paper examines present composition, on the impact of rat femur bone density and rat femur bone index, on the impact of rat blood serum calcium, serum paraoxonase, to divide rat femur bone ash, the impact of bone calcium, bone phosphorus.
Get male and female rat (body weight 160g-180g) half and half, with 3% pentobarbital sodium anesthesia, routine disinfection, aseptically extract bilateral testes or ovary, sew up the incision at random, sham operated rats is only done to sew up (not Testectomy and ovary) after abdominal operation sterilization is cut again, by rat random packet, often organize 10, grouping after performing the operation one week, by the administration of medication group, once a day, continuous 90 days, compositions administration group presses 800mg/kg, 400mg/kg, 200mg/kg is high, in, the administration of low three administration groups, positive control LONGMU ZHUANGGU KELI 0.8mg/kg, the large dark woods board Os Cervi calcium tablet 800mg/kg of positive control, matched group and model group are given and coordinative solvent.Observation index: administration terminates broken end sudden death animal, get blood separation of serum, measure S/Ca, S/P content by kit method, get rats with bilateral femur and peel meat and hetero-organization thereof off, wherein side femur does bone density scan on Dual-energy X-rays absorptionmetry, measures bone density (g/cm
2), claim femur heavy (W), survey bone long (L), dry 1 hour for 110 DEG C, then to put in Muffle furnace 200 DEG C, 400 DEG C, 600 DEG C, 800 DEG C each ashing two hours, ashing terminates, and cooling claims ash heavy (Wash), with the HNO of 6N
3survey bone ash P, Ca content after extracting, represent with the grams of 100g bone ash calcium ions or P.Above result all compares with administration group and model group, and model group and matched group compare.Experimental result is in table 1,2,3.
Table 1, this compositions are on the impact of rat femur bone density and rat femur bone index
△ △p<0.01 compares with Normal group,
*p<0.05,
*p<0.01 compares with model control group
Table 2, this compositions are on the impact of rat blood serum calcium, serum paraoxonase
△ △p<0.01 compares with Normal group,
*p<0.05,
*p<0.01 compares with model control group
Table 3, this compositions are divided rat femur bone ash, the impact of bone calcium, bone phosphorus
△ △p<0.01 compares with Normal group,
*p<0.05,
*p<0.01 compares with model control group
Above result shows that the present composition all has appreciable impact to castrated rats femoral bmd, bone weight, bone ash weight, bone calcium, bone phosphorus, makes it increase, and does not affect bone length, serum calcium is increased, less on serum paraoxonase impact.
In the present invention, compositions has increase bone density in sum, prevents and treats osteoporotic effect.
The present invention is described in detail by the following examples, but does not mean that the present invention is only limitted to this, and specific embodiments is as follows:
embodiment 1the extraction preparation of compositions
(1) Flos lupuli (Flos Humuli Lupuli) 60% alcohol reflux 2 times, when each 2, filter, filtrate recycling ethanol, add water to every ml containing 0.6g crude drug, by the AB-8 macroporous resin column of anticipating, first use deionized water eluting 4 times of column volumes, then use 70% ethanol elution, 4 times of column volumes, collect ethanol elution, reclaim ethanol, dry, obtain Flos lupuli (Flos Humuli Lupuli) total flavones;
(2) Os Cervi clear water is cleaned, and is ground into coarse powder, in autoclave, carries out high pressure extract 3 hours with the deionized water of 5 times amount, filter, filtering residue add again 4 times amount deionized waters continue to be extracted into Os Cervi loosen frangible till, filter, merge twice filtrate, let cool, oil removing, concentrated, the concentrated solution alcohol settling of 5 times amount, filter, filter residue and drying, obtains Os Cervi glycopeptide;
(3) the Os Cervi refiner after extraction glycopeptide is broken into homogenate, dry, pulverize, cross 200 mesh sieves, obtain Os Cervi activated calcium;
(4) Fructus Ligustri Lucidi 6 times of 70% alcohol reflux 3 times, each 2 hours, filters, filtrate recycling ethanol, concentrated, dry, obtains Fructus Ligustri Lucidi extract;
(5) by Flos lupuli (Flos Humuli Lupuli) total flavones 100 parts, Os Cervi glycopeptide 50 parts, Os Cervi activated calcium 200 parts, Fructus Ligustri Lucidi extract 200 parts, after mix homogeneously, adds adjuvant evenly, to obtain final product.
Claims (4)
1. one kind has the osteoporotic natural drug composition of auxiliary prevention and therapy, it is characterized in that, it is made up of the raw material of following weight parts: Flos lupuli (Flos Humuli Lupuli) total flavones 50-150 part, Os Cervi glycopeptide 25-100 part, Os Cervi activated calcium 150-400 part, Fructus Ligustri Lucidi extract 150-400 part.
2. one has the osteoporotic natural drug composition of auxiliary prevention and therapy according to claim 1, it is characterized in that, it is made up of the raw material of following weight parts: Flos lupuli (Flos Humuli Lupuli) total flavones 100 parts, Os Cervi glycopeptide 50 parts, Os Cervi activated calcium 200 parts, Fructus Ligustri Lucidi extract 200 parts.
3. the natural drug composition according to claim 1-2, its preparation method is as follows:
(1) Flos lupuli (Flos Humuli Lupuli) 30-95% alcohol reflux 2-3 time, each 2-3 hour, filter, filtrate recycling ethanol, the AB-8 macroporous resin column of concentrated solution by anticipating, first use deionized water eluting, use 60-90% ethanol elution again, collect ethanol elution, reclaim ethanol, drying, obtains Flos lupuli (Flos Humuli Lupuli) total flavones;
(2) Os Cervi clear water is cleaned, and is ground into coarse powder, in autoclave, carries out high pressure extract 3 hours with the deionized water of 5 times amount, filter, filtering residue add again 4 times amount deionized waters continue high pressure extract to Os Cervi loosen frangible, filter, merge twice filtrate, let cool, oil removing, concentrated, the concentrated solution alcohol settling of 5 times amount, filter, dry, obtain Os Cervi glycopeptide;
(3) the Os Cervi refiner after extraction glycopeptide is broken into homogenate, dry, pulverize, cross 200 mesh sieves, obtain Os Cervi activated calcium;
(4) Fructus Ligustri Lucidi 4-10 times of 40-90% alcohol reflux 2-3 time, each 1-3 hour, filters, filtrate recycling ethanol, concentrated, dry, obtains Fructus Ligustri Lucidi extract;
(5) by Flos lupuli (Flos Humuli Lupuli) total flavones, Os Cervi glycopeptide, Os Cervi activated calcium, Fructus Ligustri Lucidi extract proportionally mix homogeneously, add auxiliary materials and mixing, to obtain final product.
4. one kind has the osteoporotic natural drug composition oral formulations of auxiliary prevention and therapy, the natural drug composition described in claim 1-3 is it is characterized in that to mix with pharmaceutic adjuvant, make oral formulations, it can be any one in hard capsule, soft capsule, tablet, granule, powder, pill, teabag, medicated wine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410551423.2A CN104257762B (en) | 2014-10-17 | 2014-10-17 | A kind of pharmaceutical composition and prevention thereof and the osteoporotic purposes for the treatment of |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410551423.2A CN104257762B (en) | 2014-10-17 | 2014-10-17 | A kind of pharmaceutical composition and prevention thereof and the osteoporotic purposes for the treatment of |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104257762A true CN104257762A (en) | 2015-01-07 |
| CN104257762B CN104257762B (en) | 2016-07-06 |
Family
ID=52149419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410551423.2A Expired - Fee Related CN104257762B (en) | 2014-10-17 | 2014-10-17 | A kind of pharmaceutical composition and prevention thereof and the osteoporotic purposes for the treatment of |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104257762B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105232634A (en) * | 2015-10-12 | 2016-01-13 | 临沂草之美医药科技有限公司 | Application of pharmaceutical composition for preparing osteoporosis treating drug |
| CN105663239A (en) * | 2016-03-08 | 2016-06-15 | 宁夏医科大学 | Application of cinnamomum burmannii leaf extract in preparation of medicine used for treating osteoporosis and pharmaceutical composition of cinnamomum burmannii leaf extract |
| CN106880839A (en) * | 2015-12-14 | 2017-06-23 | 吉林省东鳌鹿业集团有限公司 | A kind of deer osteocomma and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101239083A (en) * | 2007-02-09 | 2008-08-13 | 普尔药物科技开发（深圳）有限公司 | New medical purpose of privet and pharmaceutical formulation thereof |
| CN101711161A (en) * | 2007-03-19 | 2010-05-19 | 麦特普罗泰欧米克斯有限公司 | Promote the method and composition of skeleton and articulation health |
-
2014
- 2014-10-17 CN CN201410551423.2A patent/CN104257762B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101239083A (en) * | 2007-02-09 | 2008-08-13 | 普尔药物科技开发（深圳）有限公司 | New medical purpose of privet and pharmaceutical formulation thereof |
| CN101711161A (en) * | 2007-03-19 | 2010-05-19 | 麦特普罗泰欧米克斯有限公司 | Promote the method and composition of skeleton and articulation health |
Non-Patent Citations (1)
| Title |
|---|
| 金芝贵等: "女贞子的药理作用及其临床应用进展", 《药学服务与研究》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105232634A (en) * | 2015-10-12 | 2016-01-13 | 临沂草之美医药科技有限公司 | Application of pharmaceutical composition for preparing osteoporosis treating drug |
| CN106880839A (en) * | 2015-12-14 | 2017-06-23 | 吉林省东鳌鹿业集团有限公司 | A kind of deer osteocomma and preparation method thereof |
| CN105663239A (en) * | 2016-03-08 | 2016-06-15 | 宁夏医科大学 | Application of cinnamomum burmannii leaf extract in preparation of medicine used for treating osteoporosis and pharmaceutical composition of cinnamomum burmannii leaf extract |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104257762B (en) | 2016-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105412569A (en) | Composition for increasing bone mineral density and preparation and preparation method thereof | |
| CN101428056A (en) | Health care formulation for improving osteoporosis of female in middle and old age and preparation method thereof | |
| CN101143155A (en) | Double ginseng composition and its application | |
| CN106214989A (en) | A kind of defying age, the deer's blood health-care medicated wine improving memory and preparation method thereof | |
| CN103070961A (en) | Chinese medicinal anti-bacteria health care foot-massage solution and preparation method thereof | |
| CN102068678A (en) | Traditional Chinese medicine for treating gastropathy | |
| CN104257762B (en) | A kind of pharmaceutical composition and prevention thereof and the osteoporotic purposes for the treatment of | |
| CN104721678A (en) | Application of Alpinia officinarum Hance extract in preparation of anti-osteoporosis health food and drugs | |
| CN104127861B (en) | A kind of have pharmaceutical composition increasing bone density effect and preparation method thereof | |
| CN103405755B (en) | Pharmaceutical composition for treating primary osteoporosis | |
| CN101612279A (en) | A kind of Chinese medicine preparation that promotes union of fracture | |
| CN104001157B (en) | Compound preparation of a kind of protect against osteoporosis and preparation method thereof | |
| CN103349674A (en) | Tortoise shell rana japonica oil composition for increasing bone density and preventing osteoporosis | |
| CN104225067B (en) | Chinese medicine composition, preparation method and purposes for treating postmenopausal osteoporosis | |
| CN105079400A (en) | Pharmaceutical preparation for treating osteoporosis | |
| KR20050047579A (en) | Bone disease drug composition using herb medicines | |
| CN103768158B (en) | Pharmaceutical composition of a kind of protect against osteoporosis and preparation method thereof | |
| CN106963845A (en) | It is a kind of to be used to protect female to prolong the Chinese medicine composition in spring and preparation method thereof | |
| CN106362067A (en) | Roxburg rose fruit appetite improving and digestion promoting drug composition and preparation method thereof | |
| CN102114070A (en) | Compound traditional Chinese medicine for treating osteoporosis and preparation method thereof | |
| CN102784230A (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN104189693B (en) | Traditional Chinese medicine composition for treating posemenopausal osteoporosis | |
| CN115737729B (en) | Ethnic medicine preparation for treating osteoporosis and preparation method thereof | |
| CN102552386B (en) | Anti-osteoporosis Chinese medicinal preparation and preparation method thereof | |
| CN102961518B (en) | Application for ginseng-rhizoma curculiginis combined medicine for preparation for medicine used for treating osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yin Yuhe Inventor after: Teng Guosheng Inventor after: Wu Congmei Inventor after: He Yufang Inventor after: Nan Minlun Inventor after: Zhao Quancheng Inventor before: Zhao Quancheng Inventor before: Nan Minlun Inventor before: Zhao Yuwei Inventor before: He Yufang Inventor before: Ma Jisheng Inventor before: Lv Na Inventor before: He Zhongmei |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160530 Address after: 130021 College of chemistry and life science, Yanan Road, Changchun, Jilin, China Applicant after: Changchun Polytechnic Univ. Address before: High tech Zone of Jilin province Changchun pioneering street 130012 No. 155 Jilin Provincial Academy of traditional Chinese Medicine Applicant before: Zhao Quancheng |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160706 Termination date: 20201017 |